CSS
VRTX icon

Cubist Systematic Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Cubist Systematic Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.07M Sell
10,400
-1,300
-11% -$543K 0.02% 1088
2025
Q2 		$5.21M Buy
11,700
+2,400
+26% +$1.11M 0.02% 997
2025
Q1 		$4.51M Sell
9,300
-2,800
-23% -$1.3M 0.03% 941
2024
Q4 		$4.87M Buy
+12,100
New +$5.61M 0.03% 852
2024
Q3 		– Sell
-200
Closed -$93.7K – 3543
2024
Q2 		$93.7K Hold
200
– – ﹤0.01% 2637
2024
Q1 		$83.6K Hold
200
– – ﹤0.01% 3299
2023
Q4 		$81.4K Sell
200
-36,300
-99% -$13.4M ﹤0.01% 3213
2023
Q3 		$12.7M Buy
36,500
+21,600
+145% +$7.55M 0.09% 275
2023
Q2 		$5.24M Buy
+14,900
New +$5.02M 0.03% 813
2023
Q1 		– Sell
-8,000
Closed -$2.31M – 4469
2022
Q4 		$2.31M Sell
8,000
-7,900
-50% -$2.41M 0.01% 1726
2022
Q3 		$4.6M Buy
+15,900
New +$4.57M 0.03% 1154

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cubist Systematic Strategies's VRTX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 29,923 shares — an estimated $13M sold.

Cubist Systematic Strategies first reported a position in VRTX in Q2 2014 and held it in 39 quarters. The position peaked at $29.4M in Q1 2021. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 29,923 Vertex Pharmaceuticals shares in Q2 2024, an estimated $13M.
  • Cubist Systematic Strategies first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 39 quarters.
  • Cubist Systematic Strategies's Vertex Pharmaceuticals position peaked at $29.4M in Q1 2021.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.